Gossamer Bio’s stock falls 64% on findings for Phase 2 study for hypertension drug

Shares of Gossamer Bio Inc. GOSS, -75.40% plunged 64.5% in premarket trading on Tuesday after Wall Street analysts questioned the performance of the company’s experimental hypertension drug in a...

How Comprehensive Community-Wide Hypertension Data Are Inspiring Heath Equity

It’s no secret that the best data often begets the best policy, especially when it comes to community health and wellness. Having accurate, timely, and well-informed data is often the difference maker...